Source:http://linkedlifedata.com/resource/pubmed/id/16865241
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-7-25
|
| pubmed:abstractText |
Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers. From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry. The expression of p53, p21, Cyclin A and CD31 was measured semi-quantitatively. The expression rate was classified as high when immunostaining was seen in > 5% of the tumour cells for p53 and p21, > 20% in Cyclin A and, above median vessel count for CD31. Marker expression was correlated to survival and treatment response. A high Cyclin A expression correlated significantly with improved overall (77% vs 59%, p = 0.005) and tumour-specific (81% vs 64%, p = 0.009) survival at 5 years. Also, the locoregional failure rate was significantly lower in patients with a high Cyclin A expression (12% vs 24%, p < 0.05). In a multivariate Cox analysis Cyclin A was an independent prognostic factor. A low p21 expression correlated with a reduced rate of locoregional failure (14% vs 27%, p < 0.05) but no impact on survival was found. For p53 and CD31 no significant correlations were obtained. Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD31,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin A,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1021-335X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
443-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16865241-Adult,
pubmed-meshheading:16865241-Aged,
pubmed-meshheading:16865241-Aged, 80 and over,
pubmed-meshheading:16865241-Antigens, CD31,
pubmed-meshheading:16865241-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16865241-Anus Neoplasms,
pubmed-meshheading:16865241-Carcinoma, Squamous Cell,
pubmed-meshheading:16865241-Cohort Studies,
pubmed-meshheading:16865241-Cyclin A,
pubmed-meshheading:16865241-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:16865241-Disease-Free Survival,
pubmed-meshheading:16865241-Female,
pubmed-meshheading:16865241-Humans,
pubmed-meshheading:16865241-Male,
pubmed-meshheading:16865241-Middle Aged,
pubmed-meshheading:16865241-Prospective Studies,
pubmed-meshheading:16865241-Survival Rate,
pubmed-meshheading:16865241-Treatment Outcome,
pubmed-meshheading:16865241-Tumor Markers, Biological,
pubmed-meshheading:16865241-Tumor Suppressor Protein p53
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Prognostic significance of Cyclin A in epidermoid anal cancer.
|
| pubmed:affiliation |
Centre of Gastrointestinal Disease, Ersta Hospital, SE 116 91 Stockholm, Sweden. perjohan.nilsson@erstadiakoni.se.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|